 Connection
Jennifer Laudadio to Antineoplastic Agents
This is a "connection" page, showing publications Jennifer Laudadio has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.055 |
|
|
|
-
Vatca M, Lucas JT, Laudadio J, D'Agostino RB, Waltonen JD, Sullivan CA, Rouchard-Plasser R, Matsangou M, Browne JD, Greven KM, Porosnicu M. Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol. 2014 Sep; 50(9):869-76.
Score: 0.016
-
Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA. Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer. Int J Oncol. 2013 Dec; 43(6):2057-63.
Score: 0.016
-
Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009 Sep 24; 114(13):2598-605.
Score: 0.012
-
Quigley NB, Henley DC, Hubbard RA, Laudadio J, Press RD. ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. J Mol Diagn. 2008 Sep; 10(5):475-6; author reply 476.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|